Displaying drugs 10776 - 10800 of 11695 in total
CALY-002
CALY-002 is a humanized monoclonal antibody targeting interleukin-15.
Investigational
Matched Description: … CALY-002 is a humanized monoclonal antibody targeting interleukin-15. …
BBP-671
BBP-671 is a small molecule activator of pantothenate kinases.
Investigational
Matched Description: … BBP-671 is a small molecule activator of pantothenate kinases. …
Pozanicline
ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for the treatment of several neurological disorders including Alzheimer, Attention Deficit Hyperactivity Disorder and Schizophrenia/Schizoaffective disorders. In radioligand binding studies, ABT-089 has shown selectivity toward the alpha4beta2 nAChR subtype as compared to the alpha7 and alpha1beta1deltagamma nAChR...
Investigational
Matched Description: … ABT-089 is a neuronal nicotinic acetylcholine receptor agonist that may have therapeutic utility for …
CG0070
CG0070 is investigated in clinical trials for treating bladder cancer. CG0070 is a solid. CG0070 can potentially destroy cancer cells by two different mechanisms: direct cell killing by the virus and immune-mediated cell killing stimulated by GM-CSF. CG0070, an oncolytic virus therapy with specificity for multiple cancers, has been evaluated...
Investigational
Matched Description: … CG0070 is a solid. …
Repinotan
Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective properties.
Investigational
Matched Description: … Repinotan is a high-affinity, selective, full agonist of the 5HT1A-receptor subtype with neuroprotective …
Briakinumab
Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of T-cell driven autoimmune diseases. It targets and neutralize interleukin-12 and interleukin-23, two proteins associated with inflammation, such as pro-inflammatory interleukins or tumor necrosis factor- alpha. Briakinumab represents a novel approach to treating psoriasis, Multiple...
Investigational
Matched Description: … Briakinumab is a human anti-IL-12 monoclonal antibody being developed for the treatment of a number of ... Briakinumab represents a novel approach to treating psoriasis, Multiple Sclerosis, Crohn’s Disease and …
Dimethylthiambutene
Dimethylthiambutene (N,N-Dimethyl-1-methyl-3,3-di-2-thienylallylamine, Dimethibutin, Ohton) is an opioid analgesic drug. It is now under international control under Schedule I of the UN Single Convention On Narcotic Drugs 1961, presumably due to high abuse potential, although little more information is available.
Experimental
Illicit
Dihydroxyacetone phosphate
Dihydroxyacetone phosphate is an important intermediate in lipid biosynthesis and in glycolysis. Dihydroxyacetone phosphate has been investigated for the treatment of Lymphoma, Large-Cell, Diffuse.
Investigational
Etrinabdione
Investigational
Motavizumab
Investigational
Dendritic cells vaccine
The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and effectiveness against SARS-CoV-2-induced pneumonia. With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the recombinant chimeric DC vaccine reduces the risk of virulence recovery, pre-existing anti-vector immunity, and incomplete viral inactivation.
As...
Investigational
Matched Description: … The recombinant chimeric DC vaccine is a subunit-based vaccine candidate investigated for safety and ... With a better safety profile than inactivated and live-attenuated virus and virus-vector vaccines, the …
Glyceryl 1-oleate
Experimental
Citrus junos fruit
Citrus junos fruit is a plant/plant extract used in some OTC (over-the-counter) products. It is not an approved drug.
Experimental
Matched Description: … Citrus junos fruit is a plant/plant extract used in some OTC (over-the-counter) products. …
Prinomastat
Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. Prinomastat inhibits matrix metalloproteinases (MMPs) (specifically, MMP-2, 9, 13, and 14), thereby inducing extracellular matrix degradation, and inhibiting angiogenesis, tumor growth and invasion, and metastasis. As a lipophilic agent, prinomastat crosses the blood-brain barrier.
Investigational
Matched Description: … As a lipophilic agent, prinomastat crosses the blood-brain barrier. ... Prinomastat is a synthetic hydroxamic acid derivative with potential antineoplastic activity. …
EHT899
EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune response elicited by the HBV infection. It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction in liver damage and decrease in viral load.
Investigational
Matched Description: … EHT899 is a proprietary formulation of an HBV viral protein designed to eliminate the undesirable immune ... It also apparently enhances a secondary immune response to clear the viral infection, resulting in reduction …
DP-b99
DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment of stroke, head trauma and neurological damage associated with coronary artery bypass graft.
Investigational
Matched Description: … DP-b99 is a newly developed lipophilic, cell permeable derivative of BAPTA (1,2-bis(2-aminophenoxy)ethane-N ... ,N,N',N'-tetraacetic acid), that is under development as a neuroprotectant for the potential treatment …
Edivoxetine
Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under development by Eli Lilly for attention-deficit hyperactivity disorder (ADHD) and as an antidepressant treatment. Edivoxetine failed to be approved for major depressive disorder after phase III clinical trials in 2012.
Investigational
Matched Description: … Edivoxetine is a drug which acts as a selective norepinephrine reuptake inhibitor and is currently under …
VY-HTT01
VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease progression. VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses the canonical RNA interference pathway to selectively knock down levels of HTT mRNA.
Investigational
Matched Description: … VY-HTT01 is a gene therapy designed to reduce the expression of huntingtin, thereby altering disease ... VY-HTT01 is comprised of an adeno-associated virus capsid (AAV1) and a proprietary transgene that harnesses …
XL784
XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because of its important role in blood vessel formation and cell proliferation. XL784 was specifically optimized to be MMP-1 sparing, thus potentially enhancing its safety profile and enabling higher dosing compared with other previously studied...
Investigational
Matched Description: … XL784 is a potent inhibitor of the ADAM-10 metalloprotease enzyme, a target of significant interest because …
D-Levofloxacin
A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity of bacterial DNA GYRASE, halting DNA REPLICATION.
Experimental
Matched Description: … A synthetic fluoroquinolone (FLUOROQUINOLONES) antibacterial agent that inhibits the supercoiling activity …
Sibrotuzumab
Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). It is used to treat cancer.
Investigational
Matched Description: … Sibrotuzumab is a humanized monoclonal antibody directed against fibroblast activation protein (FAP). …
Icosabutate
Icosabutate is under investigation in clinical trial NCT02373176 ([14C] Icosabutate -A Phase I Absorption, Metabolism and Excretion Study).
Investigational
Matched Description: … Icosabutate is under investigation in clinical trial NCT02373176 ([14C] Icosabutate -A Phase I Absorption …
RO-5045337
RO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With Solid Tumors).
Investigational
Matched Description: … RO-5045337 is under investigation in clinical trial NCT01164033 (A Study of RO5045337 in Patients With …
Frovocimab
Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants With High Cholesterol).
Investigational
Matched Description: … Frovocimab is under investigation in clinical trial NCT01671085 (A Study of LY3015014 in Healthy Participants …
LY2828360
LY2828360 is under investigation in clinical trial NCT01319929 (A Study of LY2828360 in Patients With Osteoarthritic Knee Pain).
Investigational
Matched Description: … LY2828360 is under investigation in clinical trial NCT01319929 (A Study of LY2828360 in Patients With …
Displaying drugs 10776 - 10800 of 11695 in total